Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED extension data in chronic spontaneous urticaria to provide additional efficacy and safety data for RhapsidoPhase II Rhapsido food allergy dose-response analysis in adults with IgE-mediated peanut allergy also to be presentedBasel, June 8th, 2026 - Novartis will present data from 10 abstracts at the Europea